Company Filing History:
Years Active: 2012-2017
Title: Agung Eviryanti: Innovator in Pharmaceutical Chemistry
Introduction
Agung Eviryanti is a notable inventor based in Kawasaki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patents. With a total of two patents to his name, Eviryanti's work focuses on compounds that have potential medicinal applications.
Latest Patents
Eviryanti's latest patents include a sulfonamide derivative and its medicinal use. This invention involves sulfonamide compounds characterized by a specific chemical structure, where a sulfonamide group is substituted with a phenyl group or a heterocyclic group containing hetero atoms. These novel compounds exhibit excellent α4 integrin-inhibitory action and include pharmaceutically acceptable salts. Another significant patent is related to pyrazolo-pyrimidine compounds, which are designed to inhibit IL-12/IL-23 production. This invention provides a pharmaceutical composition aimed at preventing or treating diseases associated with excess production of IL-12/IL-23.
Career Highlights
Throughout his career, Agung Eviryanti has worked with prominent companies in the pharmaceutical industry. He has been associated with Ea Pharma Co., Ltd. and Ajinomoto Co., Ltd., where he has contributed to various research and development projects. His expertise in medicinal chemistry has been instrumental in advancing the understanding of pharmaceutical compounds.
Collaborations
Eviryanti has collaborated with notable colleagues, including Takashi Yamamoto and Ryohei Yokoyama. These collaborations have fostered a productive environment for innovation and have led to the development of impactful pharmaceutical solutions.
Conclusion
Agung Eviryanti's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an innovator in the field. His work continues to influence the development of new medicinal compounds that have the potential to address significant health challenges.